Conbercept is an anti-VEGF recombinant fusion protein developed in China that can block the binding of VEGF to its receptors and was approved in 2013 by the China Food and Drug Administration for the treatment of wet age-related macular degeneration [7]. This evidence concerns the gene VEGFA and wet macular degeneration.